Amphotericin B deoxycholate (AmBd) has been a standard therapy for IFI but is associated with high adverse event and mortality rates. A retrospective review was undertaken to describe adverse events and clinical outcomes in adult patients with IFI treated with only AmBd as initial therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/00365540500372887 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
DMR040, a potential antifungal compound.
J Antibiot (Tokyo)
January 2025
Shanghai Duomirui Biotechnology Ltd., Shanghai, China.
Based on DMR022 [(AEEA-Gly)-AEEA-amphotericin B methyl ester, AEEA is the abbreviation of 8-amino-3,6-dioxaoctanoic acid] and DMR031 [(AEEA)-amphotericin B methyl ester], DMR040 [(AEEA)-amphotericin B methyl ester] was further designed and synthesised. Firstly, DMR040 was assessed for its antifungal activity and haemolytic toxicity with the broth dilution method and sterile defibrinated sheep blood, respectively. The minimal inhibitory concentration (MIC) of DMR040 (2 μg/mL) against Candida albicans ATCC 10231 and ATCC 90028 was reduced by 2 times compared to that of amphotericin B (1 μg/mL).
View Article and Find Full Text PDFApplication of Physiologically Based Pharmacokinetic Model to Compare the Biodistribution of Liposomal Amphotericin B With Conventional Amphotericin B Deoxycholate in Humans.
Biopharm Drug Dispos
December 2024
Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China.
Amphotericin B (AmB) has been a cornerstone in the treatment of invasive fungal infections for over 6 decades. Compared with conventional amphotericin B deoxycholate (AmB-DOC), liposomal amphotericin B has comparable efficacy but less nephrotoxicity. The main purpose of this study was to investigate the reason why liposomal amphotericin B has similar therapeutic effects but lower toxicity and the differences of distribution in humans between liposomal amphotericin B and AmB-DOC.
View Article and Find Full Text PDFScrotal abscess caused by Candida glabrata in a patient with uncontrolled diabetes mellitus and chronic renal failure.
Rev Inst Med Trop Sao Paulo
December 2024
Balikesir University, Medical Faculty, Infectious Diseases and Clinical Microbiology Department, Balikesir, Turkey.
Candida glabrata is a yeast which incidence has increased in recent years and usually causes urogenital and bloodstream infections. Its resistance to fluconazole hinders C. glabrata infections treatment.
View Article and Find Full Text PDFAmphotericin B Colloidal Dispersion is Efficacious and Safe for the Management of Talaromycosis in HIV-Infected Patients: Results of a Retrospective Cohort Study in China.
Infect Drug Resist
December 2024
Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, 400036, People's Republic of China.
Background: Amphotericin B deoxycholate (AmB-D) have potential toxic effects in the treatment of talaromycosis, and high-quality, non-generic liposomal AmB (L-AMB) is still inaccessible in many regions of China. As such, the efficacy and safety of alternative drugs warrant further investigation for the management of talaromycosis. This study aimed to compare the efficacy and safety of Amphotericin B Colloidal Dispersion (ABCD) and AmB-D for the treatment of talaromycosis in a retrospective cohort of HIV-infected patients.
View Article and Find Full Text PDFComparison of antifungal drugs in the treatment of invasive pulmonary aspergillosis: a systematic review and network meta-analysis.
Front Microbiol
December 2024
Department of Respiratory and Critical Care Medicine, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background: Voriconazole, isavuconazole, and amphotericin (AmB) formulations are currently recommended to treat invasive pulmonary aspergillosis (IPA). We aimed to estimate the efficacy of different antifungal drugs in the initial treatment of IPA.
Methods: We included all available randomized controlled trials (RCTs) evaluating first-line treatments for IPA by searching PubMed, Medline, EMBASE, the Cochrane Library, and the ClinicalTrials.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!